Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade

Key Points

• Shares of Bicara Therapeutics hit a new 52-week high (trading up to $21.05, last $20.50) after Goldman Sachs raised its price target to $16, and the stock has a consensus rating of “Moderate Buy” with analyst targets ranging as high as $42 and a consensus target of $28.
• Insiders have been net sellers recently — including the CFO and another officer — with 137,969 shares sold in the last quarter worth roughly $2.59 million, a development that could concern some investors.
• Bicara reported a Q4 EPS of ($0.68), beating the ($0.72) estimate, and the company highlights a healthy cash runway that reduces near‑term financing risk while it advances clinical programs.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price reached a new 52-week high on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded at $20.5040, with a volume of 90918 shares traded. The stock had previously closed at $19.89.

Several other equities research analysts also recently issued reports on the company. Wells Fargo & Company raised their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an "equal weight" rating in a research report on Tuesday. Citigroup began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They set an "outperform" rating for the company. Bank of America initiated coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They issued a "buy" rating and a $35.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.00.

Insider Activity at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 13,555 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total value of $246,972.10. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Raben sold 16,300 shares of Bicara Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. This trade represents a 22.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 137,969 shares of company stock worth $2,586,198.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Multiple bullish analyst moves: HC Wainwright raised its price target to $42 and kept a Buy rating, implying substantial upside if clinical progress continues. HC Wainwright raises PT to $42
• Positive Sentiment: Additional bullish reaffirmations: Citizens JPM reaffirmed a market‑outperform view with a $31 target, and Wedbush reaffirmed an Outperform with a $30 target — both signal continued analyst conviction. Analyst reaffirmations (Benzinga)
• Positive Sentiment: Clinical momentum: Seeking Alpha highlights maintaining a Buy based on ficerafusp alfa progress — phase 1/1b showed a 12‑month overall survival of ~61% and confirmed ORR ~54% with ficerafusp + KEYTRUDA, supporting the ongoing pivotal FORTIFI‑HN01 phase 3 program; mid‑2027 interim data and ASCO 2026 follow‑up are key catalysts. Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 results and cash position: Q4 2025 call/transcript noted an EPS beat vs. consensus and a healthy cash runway, reducing near‑term financing risk and supporting ongoing clinical execution. BCAX Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Mixed analyst re‑ratings with conservative valuations: Goldman Sachs raised its PT to $16 but kept a Neutral rating (implying downside vs. current levels), and Wells Fargo moved its PT to $16 with an Equal Weight — these notes cap near‑term upside for some investors. Goldman Sachs raises PT to $16 (TickerReport)
• Negative Sentiment: Insider selling: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct stake — while not necessarily a red flag on operations, insider sales can create short‑term investor concern about dilution or timing. CEO Sold Over 8,000 Company Shares

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently modified their holdings of the company. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after purchasing an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the fourth quarter worth $45,000. Finally, Larson Financial Group LLC boosted its stake in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after buying an additional 3,595 shares in the last quarter.

Bicara Therapeutics Price Performance

The stock's 50 day simple moving average is $17.21 and its two-hundred day simple moving average is $16.67. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -8.16 and a beta of -0.78.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04. As a group, analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.